Compare Medpace Holdings Inc (MEDP) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Tyson Foods, Inc. — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Tyson Foods, Inc. trades at $58.17 (market cap $20.42B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.52% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TSN | |
|---|---|---|
Market Cap | $15.08B | $20.42B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $68.75 |
52-Week Low | $308.88 | $50.72 |
Enterprise Value | $14.55B | $28.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Tyson Foods (TSN) trades at $58.245, up 0.82% today, with a bearish technical signal but mixed earnings history. The company reported Q1 2026 EPS of $0.87, beating estimates, but faces margin pressures with a net income margin of 0.81%. Recent news highlights strategic product launches and executive appointments, while cash flow trends show operational strength but negative net cash flow in 2025.
Outlook is cautiously optimistic with a consensus price target of $68.80, implying 18% upside, supported by 50% analyst buy ratings. Risks include volatile protein markets and debt levels, but long-term growth in prepared foods and dividend stability offer value. Investors should weigh near-term margin challenges against strategic initiatives and analyst confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
